Blue Fin Vision® Featured in BlackDoctor: What Black Patients Should Know About Glaucoma Clinical Trials
- Posted
- Medically Reviewed by: Mr Mfazo Hove, Consultant Ophthalmic Surgeon
- Author: Chris Dunnington
- Published: July 27, 2026
- Last Updated: July 27, 2026
TL;DR: Mr Mfazo Hove, consultant ophthalmic surgeon and founder of Blue Fin Vision®, is quoted throughout a BlackDoctor.com feature on glaucoma clinical trials. He explains why Black patients face higher glaucoma risk, earlier onset and greater sight loss, and why better representation in research shapes fairer future care.
Coverage in the Largest Health Resource for the Black Community
BlackDoctor.com describes itself as the largest online health resource for the Black community. Its feature, written by Magdalena Becker, examines why Black patients are disproportionately affected by glaucoma yet remain underrepresented in clinical trials, with Mr Hove as a lead clinical voice.
Higher Risk, Earlier Onset
On the disparities Black patients face, which include an ancestry-related component, Mr Hove says:
“Black patients also tend to present younger and with more advanced disease. Research has shown the average age at diagnosis is around 63.7 years in Black patients compared with 69.1 years in White patients, often with greater optic nerve damage already present. This is a picture of higher risk, earlier onset, and a greater chance of sight loss.”
Why Representation in Research Matters
Mr Hove explains that, for him, the issue is more than professional:
“I have experienced this personally. I took part in a clinical trial at Moorfields and saw first-hand how few participants looked like me. Many Black people remain understandably cautious about research because of historical mistrust, but when we are absent from trials, we are absent from the evidence that shapes future care.”
Reassurance About How Trials Work
Addressing a common worry, Mr Hove offers reassurance about the safeguards in properly regulated trials:
“Importantly, properly regulated glaucoma trials do not leave patients without treatment. New therapies are tested alongside established standards of care, and informed consent is central. Patients receive full information before taking part and can withdraw at any time.”
The Bigger Picture
Closing the piece, Mr Hove frames representation as something that shapes the future of care:
“Representation is not just a statistic. It can influence whether future generations receive treatments and advice that truly reflect their needs.”
Authoritative, Consultant-Led Eye Care
The coverage positions Mr Hove as an authoritative voice on glaucoma and health equity and reinforces Blue Fin Vision’s consultant-led approach to diagnosis and care.
Read the Full Coverage
Concerned About Glaucoma?
Glaucoma, often called the “silent thief of sight”, can progress without symptoms until damage has occurred. If you have a family history or are due a check, the Blue Fin Vision® team invites you to book a consultation at our consultant-led clinics across London, Hertfordshire and Essex, including Harley Street, Weymouth Street, Chelmsford, Hatfield and Chase Lodge Hospital.
